Tag - SIGY

Developments

Sigyn Therapeutics successfully completes study for gram-positive bacterial toxins

Sigyn Therapeutics (OTC: SIGY) reported that preclinical in vitro studies have validated the ability of Sigyn Therapy to deplete the presence of gram-positive bacterial toxins from human blood plasma. Sigyn...

December 1, 2021

Developments

Sigyn Therapeutics featured on NPR’s Tech Nation

Jim Joyce, CEO of Sigyn Therapeutics (OTC Markets:SIGY) was interviewed by National Public Radio’s Tech Nation about the treatment of life-threatening inflammatory conditions precipitated by cytokine storm syndrome. In...

August 30, 2021

Feature

Taming cytokine storm syndrome with Jim Joyce of Sigyn Therapeutics

As a co-founder, chairman and CEO of Sigyn Therapeutics (pronounced Sig-en) (OTCMarkets:SIGY), a medical device company developing a blood purification system to treat life-threatening inflammatory conditions, including...

August 10, 2021

Tag - SIGY

Sigyn Therapeutics successfully completes study for gram-positive bacterial toxins

Sigyn Therapeutics featured on NPR’s Tech Nation

Taming cytokine storm syndrome with Jim Joyce of Sigyn Therapeutics

General

More